A Comparison of One Versus Two Doses of Influenza Vaccine in Children Aged 5-8 Years of Age Receiving Influenza Vaccine for the First Time
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 280
- 试验地点
- 2
- 主要终点
- Comparison of antibody response after 1 dose of influenza vaccine with that after 2 doses of influenza vaccine.
研究概览
简要总结
The purpose of the study was to find out if children 5 through 8 years of age who are getting influenza vaccine for the first time should get one or two doses.
详细描述
Currently, two doses of influenza vaccine are recommended for children younger than 9 years receiving influenza vaccine for the first time. While the scientific support for 2 doses of vaccine in infants and toddlers is sound, the need for 2 doses of vaccine for adequate immunogenicity in older children is less certain. If the immunogenicity of a one-dose vaccine regimen is comparable to a two-dose regimen, then one dose would be preferable for reasons of safety, practicality and economics, and would reduce a major barrier to vaccination in this injection-adverse age group. This study compared the immunogenicity and reactogenicity of one versus two doses of influenza vaccine in children aged 5 to 8 years old receiving influenza vaccine for the first time. All children enrolled in the study received two doses of vaccine, and the immune response after one dose of vaccine was compared to the immune response after two doses of vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 8 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Immunocompetent children who are at least 5 and no more than 8 years of age on the date of the first vaccination.
- •Parents able to give informed consent and child available for all study visits.
- •Family able to understand and comply with planned study procedures.
- •Family must have telephone accessibility.
排除标准
- •Previous receipt of influenza vaccine of any kind (shot or nasal spray).
- •Active cancer or blood system abnormalities such as leukemia.
- •Immunocompromising illnesses or current receipt of immunosuppressive agents
- •Allergy to eggs or egg protein, or to gentamicin (an antibiotic that is present in trace amounts in the vaccine).
- •Any acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses.
- •Temporary Exclusion Criteria:
- •Acute disease, defined as the presence of moderate or severe illness with or without fever, at the time of enrollment. Influenza vaccine may be administered to children with minor illnesses, such as diarrhea, mild upper respiratory infection and low-grade febrile illness with an oral temperature <100.4 F.
研究组 & 干预措施
Subjects receiving vaccine
2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
干预措施: 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine (Biological)
结局指标
主要结局
Comparison of antibody response after 1 dose of influenza vaccine with that after 2 doses of influenza vaccine.
时间窗: Blood samples were obtained at 3 time points, before dose 1 of vaccine, 4 weeks after receipt of dose 1 and before dose 2, and 4 weeks after dose 2 of vaccine.
次要结局
- To describe and compare the safety profile after 1 and 2 doses of vaccine.(Study diaries were kept from the day of vaccination daily for the 4 days after vaccination.)